Candesartan cilexetil: A review of its use in essential hypertension

Drugs

Volumn 56, Issue 5, 1998, Pages 847-869

  McClellan, Karen J ^a   Goa, Karen L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN HEXETIL; ENALAPRIL; HYDROCHLOROTHIAZIDE; LIPID; LOSARTAN POTASSIUM;

BACKACHE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; COUGHING; DIARRHEA; DRUG EFFICACY; ESSENTIAL HYPERTENSION; FATIGUE; GASTROINTESTINAL ABSORPTION; GLUCOSE HOMEOSTASIS; HEADACHE; HUMAN; HYPERURICEMIA; HYPOKALEMIA; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; META ANALYSIS; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; UPPER RESPIRATORY TRACT INFECTION; VERTIGO;

EID: 0031757056     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199856050-00013     Document Type: Review

References (95)

1. Nicholls MG, Charles CJ, Crozier IG, et al. Blockade of the renin-angiotensin system. J Hypertens 1994 Dec; 12 Suppl. 10: S95-103
2. Siegl PKS, Kivlighn SD, Broten TP, et al. Pharmacology of angiotensin II receptor antagonists: comparison with renin inhibitors and angiotensin-converting enzyme inhibitors. Expert Opin Invest Drugs 1994; 3 (9): 925-44
3. Diau VJ. Molecular biology of angiotensin II biosynthesis and receptors. Can J Cardiol 1995 Aug; 11 Suppl. F: 21F-6F
4. MacFadyen RJ, Reid JL. Angiotensin receptor antagonists as a treatment for hypertension. J Hypertens 1994; 12(12): 1333-8
5. de Gasparo M, Husain A, Alexander W, et al. Proposed update of angiotensin receptor nomenclature. Hypertension 1995; 25 (5): 924-7
6. Timmermans PBMWM, Smith RD. Angiotensin II receptor subtypes: selective antagonists and functional correlates. Eur Heart J 1994 Dec; 15 Suppl. D: 79-87
7. Smith RD, Timmermans PBMWM. Human angiotensin receptor subtypes. Curr Opin Nephrol Hypertension 1994 Jan; 3: 112-22
8. Timmermans PBMWM, Wong PC, Chiu AT, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993; 45 (2): 205-51
9. Shibouta Y, Inada Y, Ojima M, et al. Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]-methyl]-1H-benzimidazole- 7-carboxylic acid (CV-11974). and its prodrug, (±)-1-(cyclohexyloxycarbonyloxy)-ethyl 2-ethoxy-1-[[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole- 7-carboxylale (TCV-116). J Pharmacol Exp Ther 1993 Jul; 266: 114-20
10. Noda M, Shibouta Y, Inada Y, et al. Inhibition of rabbit aortic angiotensin II (AII) receptor by CV-11974, a new nonpeptide AII antagonist. Biochem Pharmacol 1993 Jul 20; 46: 311-8
11. Nishikawa K, Inada Y, Shibouta Y, et al. Pharmacological profile of a novel nonpeptide angiotensin II subtype 1 receptor antagonist. TCV-116. Blood Press 1994; 3 Suppl. 5: 7-14
12. Hara M, Kiyama R, Nakajima S, et al. Kinetic studies on the interaction of nonlabeled antagonists with the angiotensin II receptor. Eur J Pharmacol Mol Pharmacol 1995 Apr 28; 289: 267-73
13. Morsing P, Brandt-Eliasson U, Abrahamsson T, Candesartan, an insurmountable antagonist of angiotensin II mediated contractile effects in isolated vascular preparations: a comparison with irbesartan, losartan and its active metabolite (EXP 3174) [abstract]. Am J Hypertens 1998 Apr. 11 (4 Pt 2): 37A
14. 1 receptor. Eur J Pharmacol 1997 Jan 14; 319: 137-46
15. 1A receptors. Astra Hässle AB, Mölndal. Sweden; 1998 (Data on file)
16. Abrahamsson T, Brandt-Eliasson U, Morsing P, et al. Candesartan causes a long-lasting antagonism of the angiotensin II receptor mediated contractile effects in isolated vascular preparations: a comparison with losartan and its active metabolite (EXP 3174) [abstract]. Am J Hypertens 1998 Apr; 11 (4 Pt 2): 36A
17. Abrahamsson T, Karp L, Brandt-Eliasson U, et al. Candesartan causes a long-lasting antagonism of the angiotensin II receptor mediated contractile effects in isolated vascular preparations: a comparison with irbesartan, losartan and its active metabolite (EXP 3174). Astra Hässle, 1998 (Data on file)
18. Delacrétaz E, Nussberger J, Biollaz J, et al. Characterization of the angiotensin II receptor antagonist TCV-116 in healthy volunteers. Hypertension 1995 Jan; 25: 14-21
19. Ogihara T, Nagano M, Higaki J. Persistent inhibition of the pressor and aldosterone responses to angiotensin-II by TCV-116 in normotensive subjects. J Cardiovasc Pharmacol 1995 Sep; 26: 490-4
20. Belz GG, Fuchs B, Malerczyk C, et al. Inhibition of angiotensin II pressor response and ex vivo angiotensin II radioligand binding by candesartan cilexetil and losartan in healthy human volunteers. J Hum Hypertens 1997 Sep; 11 Suppl. 2: S45-7
21. Ogihara T, Nagano M, Mikami H, et al. Effects of the angiotensin II receptor antagonist. TCV-116, on blood pressure and the renin-angiotensin system in healthy subjects. Clin Ther 1994 Jan-Feb; 16: 74-86
22. Nagano M, Higaki J, Mikami H, et al. Role of renin-angiotensin system in hypertension in the elderly. Blood Press 1994; 3 Suppl. 5: 130-3
23. Azizi M, Nicolet L, Chatellier G, et al. Is the differentiation of AT1 receptor antagonists feasible in normotensive volunteers? [abstract]. Am J Hypertens 1997; 15 Suppl. 4; S116
24. Fridman K, Andersson OK, Wysocki M, et al. Acute effects of candesartan cilexetil (the new angiotensin II antagonist) on systemic and renal haemodynamics in hypertensive patients. Eur J Clin Pharmacol. In press
25. Fridman K, Wysocki M, Friberg P, et al. Long-term effects of candesartan cilexetil on the systemic and renal haemodynamics in moderately hypertensive patients [abstract]. Am J Hypertens 1998 Apr; 11 (4 Pt 2): 77A
26. McInnes GT, O'Kane KPJ, Jonker J, et al. The efficacy and tolerability of candesartan cilexetil in an elderly hypertensive population. J Hum Hypertens 1997 Sep; 11 Suppl. 2; S75-80
27. Trenkwalder P, Lehtovirta M, Dahl K. Long-term treatment with candesartan cilexetil does not affect glucose homeostasis or serum lipid profile in mild hypertensives with type II diabetes. J Hum Hypertens 1997 Sep; 11 Suppl. 2: S81-83
28. Elmfeldt D, George M. Hübner R, et al. Candesartan cilexetil, a new generation angiotensin II antagonist, provides dose-dependent antihypertensive effect. J Hum Hypertens 1997 Sep; 11 Suppl. 2: S49-53
29. Mizuno K, Niimura S, Katoh K, et al. TCV-116, a newly developed angiotensin II receptor antagonist, induces regression of cardiac hypertrophy through suppression of the tissue renin-angiotensin system in spontaneously hypertensive rats. Life Sci 1994; 54(25): 1987-94
30. Takeda K, Fujita H, Nakamura K, et al. Effect of an angiotensin II receptor antagonist, TCV-116, on cardiac hypertrophy and coronary circulation in spontaneously hypertensive rats. Blood Press 1994; 3 Suppl. 5: 94-8
31. Kojima M, Shiojima I, Yamazaki T, et al. Angiotensin II receptor antagonist TCV-116 induces regression of hypertensive left ventricular hypertrophy in vivo and inhibits the intracellular signaling pathway of stretch-mediated cardiomyocyte hypertrophy in vitro. Circulation 1994 May; 89: 2204-11
32. Kugoshima T, Masuda J, Sutani T, et al. Angiotensin II receptor antagonist, TCV-116, prevents myocardial hypertrophy in spontaneously hypertensive rats. Blood Press 1994; 3 Suppl. 5: 89-93
33. Ohta K, Kim S, Hamaguchi A, et al. Effects of antihypertensive treatment on cardiac hypertrophy and collagen expression in transgenic hypertensive rats TGR (mREN2)27 [abstract]. Jpn Heart J 1995 Jul; 36 (4): 535
34. Inada Y, Wada T, Ojima M, et al. Protective effects of candesartan cilexetil (TCV-116) against stroke, kidney dysfunction and cardiac hypertrophy in stroke-prone spontaneously hypertensive rats. Clin Exp Hypertens 1997 Oct; 19: 1079-99
35. 1 receptor antagonist, TCV 116, does not prevent cardiac hypertrophy in salt-loaded Dahl salt-sensitive rats. Clin Exp Pharmacol Physiol 1996 Apr; 23: 282-6
36. Kim S, Ohta K, Hamaguchi A, et al. Angiotensin II type I receptor antagonist inhibits the gene expression of transforming growth factor-β1 and extracellular matrix in cardiac and vascular tissues of hypertensive rats. J Pharmacol Exp Ther 1995 Apr; 273: 509-15
37. Fujiwara H, Minatoguchi S, Tomita M, et al. Effects of TCV-116 (candesartan cilexetil) on left ventricular hypertrophy and glucose tolerance in patients with essential hypertension [in Japanese]. Rinsho lyaku 1996; 12 (16): 3281-97
38. Mitsunami K, Takahashi M, Endo S, et al. Effects of candesartan cilexetil (TCV-116), an angiotensin II receptor antagonist, on cardiac hypertrophy and cardiac function [in Japanese]. Shinyaku to Rinsho 1996 Sep; 45: 1655-61
39. Kawabata M, Takabatake T, Ohta H, et al. Effects of an angiotensin II receptor antagonist, TCV-116, on renal baemodynamics in essential hypertension. Blood Press 1994; 3 Suppl. 5: 117-21
40. Ise T, Takakuwa H, Yokoyama H, et al. Effects of an angiotensin II receptor antagonist. TCV-116 (candesartan cilexetil) on renal function in essential hypertension [in Japanese]. Rinsho Iyaku 1996; 12 (16): 3265-80
41. Forsblom C, Trenkwalder P, Dahl K, et al. Candesartan cilexetil, a novel angiotensin II antagonist reduces microalbuminuria in patients with type II diabetes mellitus and mild hypertension [abstract]. Am J Hypertens 1997 Apr; 10 (4 Pt 2): 86A
42. Okada H, Suzuki H, Kanno Y, Renal responses to angiotensin receptor antagonist and angiotensin-convening enzyme inhibitor in partially nephrectomized spontaneously hypertensive rats. J Cardiovasc Pharmacol 1995 Oct; 26: 564-9
43. Kanno Y, Okada H, Suzuki H, et al. Nonpeptide angiotensin II type I receptor antagonist prevents nephrosclerosis in hypertensive rats. Blood Press 1994; 3 Suppl. 5: 67-70
44. Noda M, Fukuda R, Matsuo T, et al. Effects of candesartan cilexetil (TCV-116) and enalapril in 5/6 nephrectomized rats. Kidney Int 1997 Dec; 52 Suppl. 63: S136-139
45. Yoshiyama M, Kim S, Yamagishi H, et al. Cardioprotective effect of the angiotensin II type I receptor antagonist TCV-116 on ischemia-reperfusion injury. Am Heart J 1994 Jul; 128: 1-6
46. Nishikimi T, Yamagishi H, Takeuchi K. An angiotensin II receptor antagonist attenuates left ventricular dilatation after myocardial infarction in the hypertensive rat. Cardiovasc Res 1995 Jun; 29: 856-61
47. Kitayoshi T. Angiotensin II-receptor antagonists in congestive heart failure: implications of preclinical study results [abstract]. International Symposium on Angiotensin II Antagonism; 1997 Sep 29; London, 11-12
48. Tanaka A, Matsumori A, Wang W. An angiotensin II receptor antagonist reduces myocardial damage in an animal model of myocarditis. Circulation 1994 Oct: 90 (Pt 1): 2051-5
49. Tagawa K, Takenoyama T, Iino K, et al. Effects of candesartan cilexetil (TCV-116) on cerebral blood flow of hypertensive patients with cerebrovascular diseases [in Japanese]. Rinsho Iyaku 1996; 12 (16): 3319-31
50. Iimura O, Shimamoto K, Matsuda K, et al. Effects of angiotensin receptor antagonist and angiotensin converting enzyme inhibitor on insulin sensitivity in fructose-fed hypertensive rats and essential hypertensives. Am J Hypertens 1995 Apr; 8 (4 Pt 1): 353-7
51. Shimamoto K, Masuda A, Miyazaki Y, et al. Effects of an angiotensin II receptor antagonist, candesartan cilexetil (TCV-116), on insulin sensitivity in essential hypertension patients [in Japanese]. Rinsho Iyaku 1996; 12(1): 25-32
52. Kajiyama G, Matsuura H, Hayashi K, et al. The effect of TCV-116, an angiolensin II receptor antagonist, on lipid metabolism in patients with essential hypertension [in Japanese]. Rinsho Iyaku 1996; 12 (16): 3299-317
53. Andersson O, Fridman K, Wysocki M, et al. Acute effects of candesartan cilexetil on the systemic and renal haemodynamics in hypertensive patients (abstract). Am J Hypertens 1997; 15 Suppl. 4: S114
54. Astra Merck. Atacand™ (candesartan cilexetil) prescribing information. Wayne, PA, USA, 1998
55. 14C-candesartan cilexetil in healthy volunteers. J Hum Hypertens 1997 Sep; 11 Suppl. 2: S27-28
56. Hühner R, Hogemann AM, Sunzel M, et al. Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers. J Hum Hypertens 1997 Sep; 11 Suppl. 2: S19-25
57. Kajiwara E, Azuma K, Ninomiya T, et al. Pharmacokinetic study of candesartan cilexetil, an angiotensin II receptor antagonist, in patients with hepatic impairment [in Japanese]. Rinsho Iyaku 1996; 12 (16): 3353-68
58. Riddell JG. Bioavailability of candesartan is unaffected by food in healthy volunteers administered candesartan cilexetil. J Hum Hypertens 1997 Sep; 11 Suppl. 2: S29-30
59. de Zeeuw D, Remuzzi G, Kirch W. Pharmacokinetics of candesartan cilexetil in patients with renal or hepatic impairment. J Hum Hypertens 1997 Sep; 11 Suppl. 2: S37-42
60. Miwa K, Murakami H, Masaki K, et al. In vitro metabolism of candesartan cilexetil [abstract]. In: 1st International Symposium on Angiotensin II Antagonism; 1997 Sep 28-Oct 1; London: 1997
61. Meineke I, Feltkamp H, Hogemann A, et al. Pharmacokinetics and pharmacodynamics of candesartan after administration of its pro-drug candesartan cilexetil in patients with mild to moderate essential hypertension - a population analysis. Eur J Clin Pharmacol 1997 Nov-Dec; 53: 221-8
62. Jonkman JHG, van Lier JJ, van Heiningen PNM, et al. Pharmacokinetic drug interaction studies with candesartan cilexetil. J Hum Hypertens 1997 Sep; 11 Suppl. 2: S31-5
63. Heuer HJ, Schöndorfer G, Hogemann AM. Twenty-four hour blood pressure profile of different doses of candesartan cilexetil in patients with mild to moderate hypertension. J Hum Hypertens 1997 Sep; 11 Suppl. 2: S55-6
64. Sever P, Michel J, Voet B. Candesartan cilexetil (CC): a metaanalysis of time-to-effect relationship [abstract]. Am J Hypertens 1998 Apr; 11 (4 Pt 2): 79A
65. Bell TP, DeQuattro V, Lasseter KC, et al. Effective dose range of candesartan cilexetil for systemic hypertension. Am J Cardiol 1999. In press
66. Reif M, White WB, Pagan TC, et al. Effects of candesartan cilexetil in patients with systemic hypertension. Am J Cardiol 1998. In press
67. Zuschke CA, Halim A, Keys I. The angiotensin-II receptor blocker candesartan cilexetil provides 24-hour blood pressure control with once-a-day administration in mild-to-moderate hypertension [abstract]. Am J Hypertens 1998 Apr; 11 (4 Pt 2): 107A
68. Andersson OK, Neldam S. The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan. Blood Press 1998; 7: 53-9
69. Franke H. Antihypertensive effects of candesartan cilexetil, enalapril and placebo. J Hum Hypertens 1997 Sep; 11 Suppl. 2: 61-2
70. Franke H, Hermann WM, Magin SG. Comparison of the efficacy and safety of candesartan cilexetil 4, 8 and 12 mg with placebo and enalapril 10 mg in patients with mild to moderate essential hypertension [abstract]. Am J Hypertens 1997 Apr; 10 (4 Pt 2): 90A
71. Zanchetti A, Omboni S, Di Biagio C, et al. Candesartan cilexetil and enalapril are of equivalent efficacy in patients with mild to moderate hypertension. J Hum Hypertens 1997 Sep; 11 Suppl. 2: S57-59
72. Plouin P-F. Combination therapy with candesartan cilexetil plus hydrochlorothiazide in patients unresponsive to low-dose hydrochlorothiazide. J Hum Hypertens 1997 Sep; 11 Suppl. 2: S65-66
73. Oparil S, Ripley E, Candesartan Study Investigators. Candesartan cilexetil enhances blood pressure reduction in severe (stage 3, JNC-VI) hypertensive patients inadequately controlled with HCTZ [abstract]. Am J Hypertens 1998 Apr; 11 (4 Pt 2): 121A
74. Ripley E, Oparil S, Candesartan Study Investigators. The addition of candesartan to HCTZ enhances blood pressure reduction in Black patients with severe (stage 3, JNC-VI) hypertension (abstract). Am J Hypertens 1998 Apr; 11 (4 Pt 2): 119A
75. Philipp T, Letzel H, Arens H-J. Dose-finding study of candesartan cilexetil plus hydrochlorothiazide in patients with mild to moderate hypertension. J Hum Hypertens 1997 Sep; 11 Suppl. 2: S67-68
76. McInnes GT, Istad H, Keinänen-Kiukaanniemi S, et al. Combination of candesartan cilexetil/hydrochlorothiazide 8/12.5 mg has a similar antihypertensive effect and is better tolerated than lisinopril/hydrochlorothiazide 10/12.5 mg [abstract]. Am J Hypertens 1998 Apr; 11 (4 Pt 2): 109A
77. Farsang C, Kawecka-Jaszcz K, Langan J, et al. Antihypertensive effects and tolerabitity of candesartan cilexetil, amlodipine and their combination (abstract). Am J Hypertens 1997 Apr; 10 (4 Pt 2): 80A
78. Neldam S, Forsén B. Long term safely and tolerability of candesartan cilexetil (8 and 16 mg) in relation to hydrochlorothiazide (12.5 and 25 mg) in the elderly hypertensive patient. Astra Hässle; SH-AHM-0007; 15 Mar 1998 (Data on file)
79. Ogihara T, Matsuoka H, Nakagawa M. Efficacy and safety of TCV-116 (candesartan cilexetil), an angiotensin II receptor antagonist, in the elderly with hypertension [in Japanese]. Rinsho Iyaku 1996; 12 (16): 3211-28
80. Fujishima M, Okuda S, Kubo M, et al. Efficacy and safety of candesartan cilexetil (TCV-116) in hypertensive patients with renal failure [in Japanese]. Rinsho Iyaku 1996; 12(11): 2343-71
81. MacGregor GA, Antonios TFT, He FJ. Efficacy of candesartan cilexetil alone or in combination with amlodipine or amlodipine plus hydrochlorothiazide in patients with moderate to severe essential hypertension. Takeda (Data on file)
82. Sever P, Holzgreve H. Long-term efficacy and tolerability of candesartan cilexetil in patients with mild to moderate hypertension. J Hum Hypertens 1997 Sep; 11 Suppl. 2: S69-73
83. Belcher G, Hübner R, George M, et al. Candesartan cilexetil: safely and tolerability in healthy volunteers and patients with hypertension. J Hum Hypertens 1997 Sep; 11 Suppl. 2: S85-9
84. Belcher G, Hübner R, George M, et al. Safety and tolerability of candesartan cilexetil in the elderly [abstract]. J Hypertens 1998; 16 Suppl. 2: S249
85. Arakawa K, Ogihara T, Iimura O, et al. Evaluation of clinical usefulness of TCV-116 (candesartan cilexetil) in patients with essential hypertension: a double-blind, parallel group-comparison study using enalapril maleate as control drug [in Japanese]. Rinsho Iyaku 1996; 12 (12): 2613-61
86. Tanser P, Campbell LM, Carranza J, et al. Candesartan cilexetil is not associated with cough in patients with enalapril-induced cough [abstract]. Am J Hypertens 1998 Apr; 11 (4 Pt 2): 122A
87. Andersson OK, Neldam S. A comparison of the antihypertensive effects of candesartan cilexetil and losartan in patients with mild to moderate hypertension. J Hum Hypertens 1997 Sep; 11 Suppl. 2: S63-4
88. Astra Hässle. Candesartan cilexetil International Data Sheet version 2. Sweden; 1997
89. Guidelines Subcommittee of the WHO/ISH Mild Hypertension Liaison Committee. 1993 Guidelines for the management of mild hypertension. Memorandum from a World Health Organization/International Society of Hypertension meeting. Hypertension 1993 Sep; 22: 392-403
90. Chalmers J, Zanchetti A. The 1996 report of a World Health Organization expert committee on hypertension control. J Hypertens 1996 Aug; 14: 929-33
91. Joint National Committee on Prevention Detection Evaluation and Treatment of High Blood Pressure and the National High Blood Pressure Education Program Coordinating Committee. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997 Nov 24; 157: 2413-46
92. Mincieli G. Hypertension: the pressure's on. R D Direct 1997 Jul-Aug; 3: 24-6
93. Lacourcière Y, Lefebvre J. Modulation of the renin-angiotensin-aldosterone system and cough. Can J Cardiol 1995; 11 Suppl. F: 33F-9F
94. Tan SA, Berk LS, Tan LG. Increased tachykinins substance P and neurokinin A, not bradykinin, cause the ACE inhibitor-induced cough [abstract]. J Am Coll Cardiol 1997 Feb; 29 Suppl. A: 41
95. Wyeth Verdia labeling should mention liver enzyme abnormalities of unknown clinical significance, FDA cmte, says in recommending approval of All inhibitor. FDC Pink Sheet: 2 Feb 1998; 3-5